{"success":true,"data":{"pressRelease":{"id":"168614","rtpr_id":"nGNXbcRXqc-20261014","ticker":"CC","exchange":"NYSE","all_tickers":["CC"],"title":"$CC Investors: A Securities Fraud Class Action is Pending on behalf of Chemours Investors that Lost Money after 18% Stock Drop – Contact BFA Law by December 7 Deadline","author":"Globe Newswire","published_at":"2026-10-14T10:47:00.363Z","article_body":"NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=3JtiCDXoFhuYmEsEFZO-JXZYJYpxxBaQqR6sCLyYuTg3gHU8kOnMc2iWQFFXyfX3hYX3N71MLYOBf5Aa8B3N73IDgpv2LYK109NEsyOuJ0JAHAcGheI5qTKIgA7L9Aoint9yhyQvzApNkcoU9iJAYjEKNTzsqNsccJDXQlInVHI=)\nannounces that a class action lawsuit has been filed against The Chemours\nCompany (NYSE:CC) and certain of the company’s senior executives for\nsecurities fraud after a significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Chemours, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit.\n\nKey Details of the Chemours ($CC) Class Action:\n* Lead Plaintiff Deadline: December 7, 2026\n* Alleged Misconduct: Securities fraud alleging Chemours misrepresented the\nstrength of demand for its Opteon products\n* Stock Drop: August 5, 2026 – 18.63% Stock Drop\n* Court: U.S. District Court for the District of Delaware\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/chemours-class-action-lawsuit) to discuss your\nrights\nInvestors have until December 7, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nChemours securities. The class action is pending in the U.S. District Court\nfor the District of Delaware. It is captioned Darcy v. The Chemours Company,\nNo. 26-cv-1299.\n\nWhy is Chemours Being Sued for Securities Fraud?\n\nChemours offers a range of industrial and specialty chemical products,\nincluding Opteon, a set of refrigeration chemicals with a reduced\nozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act,\nwhich directed the EPA to oversee the transition to alternative refrigerants\nthat present a lesser impact to the ozone layer.\n\nAccording to the complaint, Chemours stated that continued adoption of the AIM\nAct drove sustained growth for its Opteon products. Chemours stated that the\n“sustained double-digit” Opteon expansion would be “driven by the\ncontinued regulatory adoption” of the AIM Act. What’s more, Chemours\nprovided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA\nguidance of $800M – $900M, driven by “higher . . . demand” in its Opteon\nsegment.\n\nAs alleged, Chemours failed to disclose that customers were already\noversupplied with Opteon products because of the AIM Act transition, leading\nto an “oversupplied channel heading into 2026.”\n\nWhy did Chemours’s Stock Drop?\n\nOn August 4, 2026, Chemours announced Q2 2026 financial results, revealing an\napproximately 1% year-over-year decrease in net sales and cutting 2026\nadjusted EBITDA guidance by about 11% (to $775M – $825M from $800M –\n$900M). Chemours also revealed that customers had “built additional\ninventory” of Opteon products the prior year, that aftermarket channels had\nbeen filled, and that Chemours was selling into an “oversupplied channel\nheading into 2026.”\n\nOn this news, Chemours’s stock dropped $3.34 per share, or 18.63%, from a\nclosing price of $17.93 per share on August 4, 2026, to $14.59 per share on\nAugust 5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Chemours, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360, and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nBFA’s notable successes include a recovery of over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbcRXqc-20261014","title":"$CC Investors: A Securities Fraud Class Action is Pending on behalf of Chemours Investors that Lost Money after 18% Stock Drop – Contact BFA Law by December 7 Deadline","author":"Globe Newswire","ticker":"CC","created":"2026-10-14T10:47:00.363Z","tickers":["CC"],"exchange":"NYSE","article_body":"NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=3JtiCDXoFhuYmEsEFZO-JXZYJYpxxBaQqR6sCLyYuTg3gHU8kOnMc2iWQFFXyfX3hYX3N71MLYOBf5Aa8B3N73IDgpv2LYK109NEsyOuJ0JAHAcGheI5qTKIgA7L9Aoint9yhyQvzApNkcoU9iJAYjEKNTzsqNsccJDXQlInVHI=)\nannounces that a class action lawsuit has been filed against The Chemours\nCompany (NYSE:CC) and certain of the company’s senior executives for\nsecurities fraud after a significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Chemours, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit.\n\nKey Details of the Chemours ($CC) Class Action:\n* Lead Plaintiff Deadline: December 7, 2026\n* Alleged Misconduct: Securities fraud alleging Chemours misrepresented the\nstrength of demand for its Opteon products\n* Stock Drop: August 5, 2026 – 18.63% Stock Drop\n* Court: U.S. District Court for the District of Delaware\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/chemours-class-action-lawsuit) to discuss your\nrights\nInvestors have until December 7, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nChemours securities. The class action is pending in the U.S. District Court\nfor the District of Delaware. It is captioned Darcy v. The Chemours Company,\nNo. 26-cv-1299.\n\nWhy is Chemours Being Sued for Securities Fraud?\n\nChemours offers a range of industrial and specialty chemical products,\nincluding Opteon, a set of refrigeration chemicals with a reduced\nozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act,\nwhich directed the EPA to oversee the transition to alternative refrigerants\nthat present a lesser impact to the ozone layer.\n\nAccording to the complaint, Chemours stated that continued adoption of the AIM\nAct drove sustained growth for its Opteon products. Chemours stated that the\n“sustained double-digit” Opteon expansion would be “driven by the\ncontinued regulatory adoption” of the AIM Act. What’s more, Chemours\nprovided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA\nguidance of $800M – $900M, driven by “higher . . . demand” in its Opteon\nsegment.\n\nAs alleged, Chemours failed to disclose that customers were already\noversupplied with Opteon products because of the AIM Act transition, leading\nto an “oversupplied channel heading into 2026.”\n\nWhy did Chemours’s Stock Drop?\n\nOn August 4, 2026, Chemours announced Q2 2026 financial results, revealing an\napproximately 1% year-over-year decrease in net sales and cutting 2026\nadjusted EBITDA guidance by about 11% (to $775M – $825M from $800M –\n$900M). Chemours also revealed that customers had “built additional\ninventory” of Opteon products the prior year, that aftermarket channels had\nbeen filled, and that Chemours was selling into an “oversupplied channel\nheading into 2026.”\n\nOn this news, Chemours’s stock dropped $3.34 per share, or 18.63%, from a\nclosing price of $17.93 per share on August 4, 2026, to $14.59 per share on\nAugust 5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Chemours, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360, and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nBFA’s notable successes include a recovery of over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T10:47:00.412474382Z","server_sent_at_ms":1791974820412},"received_at":"2026-10-14T10:47:00.462Z","source_url":null},"analysis":{"id":"156871","press_release_id":"168614","analysis_json":{"industry":{"label":"Chemicals","sector":"Materials"},"redFlags":["pending securities fraud class action alleging Opteon demand misrepresentation","prior 18.63% single-day stock drop on guidance cut"],"eventType":"legal_litigation","narrative":"Plaintiff law firm Bleichmar Fonti & Auld announced a pending securities fraud class action against Chemours (NYSE: CC) in the U.S. District Court for the District of Delaware, with a December 7, 2026 lead plaintiff deadline.\n\nThe suit alleges Chemours misrepresented demand for its Opteon refrigerant products, concealing a customer-oversupplied channel ahead of 2026.\n\nThe underlying catalyst was an 18.63% stock drop on August 5, 2026, after Chemours cut 2026 adjusted EBITDA guidance to $775M-$825M from $800M-$900M. This is law-firm solicitation, not a new issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine plaintiff-firm class action solicitation -- suppress."},"keyFigures":{"customDimensions":{"stock_drop_pct":"18.63%","guidance_cut_ebitda":"$775M-$825M (from $800M-$900M)","lead_plaintiff_deadline":"December 7, 2026"}},"namedEntities":{"people":[{"name":"Adam McCall","role":"BFA Law contact attorney"}],"products":["Opteon"],"companies":[{"name":"The Chemours Company","ticker":"CC","relationship":"target of class action"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$800M – $900M","context":"prior 2026 adjusted EBITDA guidance"},{"amount":"$775M – $825M","context":"reduced 2026 adjusted EBITDA guidance"},{"amount":"$3.34","context":"per-share stock decline on August 5, 2026"},{"amount":"$17.93","context":"closing price August 4, 2026"},{"amount":"$14.59","context":"closing price August 5, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm (BFA Law) solicitation notice regarding a previously filed securities class action. No new issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"CC"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Plaintiff law firm Bleichmar Fonti & Auld announced a pending securities fraud class action against Chemours (NYSE: CC) in the U.S. District Court for the District of Delaware, with a December 7, 2026 lead plaintiff deadline.\n\nThe suit alleges Chemours misrepresented demand for its Opteon refrigerant products, concealing a customer-oversupplied channel ahead of 2026.\n\nThe underlying catalyst was an 18.63% stock drop on August 5, 2026, after Chemours cut 2026 adjusted EBITDA guidance to $775M-$825M from $800M-$900M. This is law-firm solicitation, not a new issuer disclosure.","key_figures":{"customDimensions":{"stock_drop_pct":"18.63%","guidance_cut_ebitda":"$775M-$825M (from $800M-$900M)","lead_plaintiff_deadline":"December 7, 2026"}},"named_entities":{"people":[{"name":"Adam McCall","role":"BFA Law contact attorney"}],"products":["Opteon"],"companies":[{"name":"The Chemours Company","ticker":"CC","relationship":"target of class action"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$800M – $900M","context":"prior 2026 adjusted EBITDA guidance"},{"amount":"$775M – $825M","context":"reduced 2026 adjusted EBITDA guidance"},{"amount":"$3.34","context":"per-share stock decline on August 5, 2026"},{"amount":"$17.93","context":"closing price August 4, 2026"},{"amount":"$14.59","context":"closing price August 5, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T10:47:05.770Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":5288,"modelName":"glm-5.3-flashx"}}